(Gastrografin Use in Small Bowel Obstruction Caused by Adherences) (GUSBOCA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00601809 |
Recruitment Status :
Completed
First Posted : January 28, 2008
Last Update Posted : January 28, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Adhesive small intestine obstruction (ASIO) is an important cause of hospital admission and a very common disease. Any improvement in this field will benefit many patients by reducing the operative rate. Patients with this disease are difficult to evaluate and to manage and their treatment is controversial. Emergency surgery is mandatory when strangulation is suspected or in the case of total obstruction. On the other hand, conservative non-operative treatment is indicated in the case of partial obstruction. The role of water-soluble contrast medium (Gastrografin®: GG) in ASIO is still debated with regard to the therapeutic value.
The aim of our study was to determine the therapeutic role of Gastrografin in patients with small intestine obstruction without strangulation caused by adherences (ASIO).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Adhesive Small Intestine Obstruction | Other: traditional conservative treatment (TT) Drug: Gastrografin®: G | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 76 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Gastrografin Use in Small Bowel Obstruction Caused by Adherences |
Study Start Date : | September 2003 |
Actual Study Completion Date : | November 2006 |

Arm | Intervention/treatment |
---|---|
Experimental: GG |
Drug: Gastrografin®: G
The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
Other Name: water-soluble contrast medium (Gastrografin®: G) meal |
TT |
Other: traditional conservative treatment (TT)
In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction. |
- The operative rate in ASIO patients [ Time Frame: Within 72 hours and during hospital stay ]
- The incidence of major and minor complications of treatments in the two arm [ Time Frame: 1 year ]
- The ASIO recurrences [ Time Frame: 1 year ]
- The time to resolution of obstruction [ Time Frame: Within hospital stay ]
- The length of hospital stay [ Time Frame: Within hospital admission period ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patients (>18 years)
- History of previous abdominal surgical procedures
- Clinical and radiological evidence of adhesive small intestine obstruction without signs of strangulation and peritonism
- ASA I-III patients
- Informed consent
Exclusion Criteria:
- Suspicion of strangulation
- Actual presence or high suspicion of intra-abdominal malignancy
- Suspicion or history of peritoneal carcinomatosis
- active inflammatory bowel disease
- Positive history of radiotherapy on the abdominal region
- Obstructed hernias

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00601809
Italy | |
S.Orsola-Malpighi University Hospital - University of Bologna | |
Bologna, Italy | |
Emergency Surgery Department - University of Modena | |
Modena, Italy |
Principal Investigator: | Fausto Catena, MD, PhD | S.Orsola-Malpighi University Hospital - University of Bologna | |
Principal Investigator: | Luca Ansaloni, MD | S.Orsola-Malpighi University Hospital - University of Bologna | |
Principal Investigator: | Margherita Gavioli, MD | University of Modena | |
Principal Investigator: | Salomone Di Saverio, M.D. | S.Orsola-Malpighi University Hospital - University of Bologna |
Responsible Party: | Dr. Fausto Catena M.D. PhD, S. Orsola Malpighi University Hospital - University of Bologna |
ClinicalTrials.gov Identifier: | NCT00601809 |
Other Study ID Numbers: |
GUSBOCA |
First Posted: | January 28, 2008 Key Record Dates |
Last Update Posted: | January 28, 2008 |
Last Verified: | January 2008 |
Gastrointestinal Adhesive Small Intestine Obstruction Oral water soluble contrast |
Non-operative Conservative Management Operative rate Hospital stay |
Intestinal Obstruction Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |